Drug safety is about availability, affordability and transparency of the supply chain

Here you will find all the materials from the 21st Health Market Forum

- It is worth noting that STADA Pharm has a number of generic drugs and medical devices in its portfolio - said Ricardas Grazulis , CEO of STADA Pharm, during the 21st Health Market Forum.

- I believe that European Union member states should include generic drugs in their reimbursement system, which would solve two main challenges that we face in the European Union countries - he added.

He pointed out that the first concerns product affordability, and the second concerns accessibility. He believes that moving in this direction would make it easier for European patients to access products that are more affordable.

He emphasized that when discussing logistical barriers to drug introduction, in addition to production capacity, logistics and storage should also be taken into account.

"Without these three elements, we can discuss production all we want, but it won't bring us any closer to solving the fundamental problems. We need collaboration between the private and public sectors to increase transparency across the entire value chain. This will allow all stakeholders in the supply chain to have insight into warehouse movements and inventory levels at any point, allowing them to react when they fall too low," he noted.

"Remember to use the medication according to your doctor's instructions and the information in the leaflet to eliminate the risk of incorrect dosing. This allows you to use the medication to its full potential without exposing yourself to danger," reminded Ricardas Grazulis.

Copyrighted material - reprint rules are specified in the regulations .